|
US7147851B1
(en)
*
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
|
US6787523B1
(en)
*
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7090845B2
(en)
*
|
1998-05-13 |
2006-08-15 |
Genentech, Inc. |
Diagnosis and treatment of hepatic disorders
|
|
AU2011226857B2
(en)
*
|
1998-05-13 |
2013-09-19 |
Genentech, Inc. |
Diagnosis and treatment of hepatic disorders
|
|
CA2352963A1
(en)
*
|
1998-11-25 |
2000-06-02 |
The Government Of The United States Of America As Represented By The Sec Retary, Department Of Health And Human Services |
Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases
|
|
DE60020955T2
(de)
*
|
1999-04-22 |
2006-05-11 |
Biogen Idec Ma Inc., Cambridge |
Verfahren zur behandlung einer fibrose unter verwendung eines antagonisten der integrin alpha-4 untereinheit
|
|
AU2006220426B2
(en)
*
|
2000-04-14 |
2008-10-30 |
Genentech Inc. |
Method of administering an antibody
|
|
US20010046496A1
(en)
*
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
|
US7521053B2
(en)
*
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US7658924B2
(en)
*
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
ATE457741T1
(de)
*
|
2001-12-17 |
2010-03-15 |
Univ Cardiff |
Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden
|
|
CA2473144C
(en)
|
2002-02-05 |
2013-05-28 |
Genentech, Inc. |
Protein purification
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
HUE025101T2
(en)
|
2002-04-26 |
2016-02-29 |
Genentech Inc |
Purification of proteins other than affinity purification
|
|
PT2371392E
(pt)
*
|
2002-05-02 |
2015-10-07 |
Wyeth Holdings Llc |
Conjugados de derivado da caliqueamicina - transportador
|
|
GB0210121D0
(en)
*
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
|
CA2512729C
(en)
*
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
UA87453C2
(ru)
*
|
2003-02-01 |
2009-07-27 |
Вайет |
Применения фрагмента ав для лечения болезни альцгеймера
|
|
JP4599355B2
(ja)
|
2003-07-28 |
2010-12-15 |
ジェネンテック， インコーポレイテッド |
プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減
|
|
JP2007504144A
(ja)
|
2003-08-26 |
2007-03-01 |
ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド ア ボディー コーポレイト |
セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法
|
|
EP2135619A1
(en)
|
2003-12-10 |
2009-12-23 |
Millennium Pharmaceuticals, Inc. |
Humanized anti-CCR2 antibodies and methods of use therefor
|
|
EP1709080B1
(en)
|
2004-01-09 |
2011-03-09 |
Pfizer Inc. |
ANTIBODIES TO MAdCAM
|
|
US7655229B2
(en)
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
|
US7662926B2
(en)
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
|
EP1784426B1
(en)
|
2004-09-03 |
2011-11-23 |
Genentech, Inc. |
Humanized anti-beta7 antagonists and uses therefor
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
WO2006066089A1
(en)
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
WO2007007160A2
(en)
*
|
2005-07-11 |
2007-01-18 |
Pfizer Limited |
Anti-madcam antibodies to treat fever
|
|
WO2007007151A2
(en)
*
|
2005-07-11 |
2007-01-18 |
Pfizer Limited |
Use of anti-mad-cam antibody for the treatment of emphysema
|
|
US20070122404A1
(en)
*
|
2005-11-17 |
2007-05-31 |
O'keefe Theresa L |
Humanized immunoglobulin reactive with alpha4beta7 integrin
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
FR2902799B1
(fr)
|
2006-06-27 |
2012-10-26 |
Millipore Corp |
Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
|
|
US8362217B2
(en)
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
|
WO2008079302A2
(en)
|
2006-12-21 |
2008-07-03 |
Millipore Corporation |
Purification of proteins
|
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
|
KR101431856B1
(ko)
|
2007-01-22 |
2014-08-27 |
제넨테크, 인크. |
항체의 고분자전해질 침전 및 정제
|
|
EP2129397B1
(en)
*
|
2007-03-02 |
2018-10-31 |
Amgen, Inc. |
Methods and compositions for treating tumor diseases
|
|
EP2125892A2
(en)
*
|
2007-03-20 |
2009-12-02 |
Millennium Pharmaceuticals, Inc. |
Nucleic acids encoding humanized immunoglobulin that binds a4b7 integrin
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
PL2158315T3
(pl)
|
2007-06-25 |
2016-10-31 |
|
Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych
|
|
PL4365189T3
(pl)
|
2007-07-09 |
2025-05-26 |
F. Hoffmann-La Roche Ag |
Zapobieganie redukcji wiązania disiarczkowego podczas rekombinacyjnego wytwarzania polipeptydów
|
|
ES2498040T3
(es)
*
|
2007-07-27 |
2014-09-24 |
Janssen Alzheimer Immunotherapy |
Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
PE20091434A1
(es)
|
2007-10-30 |
2009-10-17 |
Genentech Inc |
Purificacion de anticuerpos por cromatografia de intercambio cationico
|
|
EP2243829B1
(en)
*
|
2008-01-11 |
2014-08-20 |
Astellas Pharma Inc. |
IMPROVED HUMANIZED ANTI-HUMAN alpha9-INTEGRIN ANTIBODY
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
WO2009151514A1
(en)
|
2008-06-11 |
2009-12-17 |
Millipore Corporation |
Stirred tank bioreactor
|
|
DK2848625T3
(da)
|
2008-08-14 |
2019-10-07 |
Genentech Inc |
Fremgangsmåder til fjernelse af en kontaminant under anvendelse af ion bytningsmembrankromatografi med forskydning af naturligt forekommende proteiner
|
|
WO2010030670A2
(en)
|
2008-09-10 |
2010-03-18 |
Genentech, Inc. |
Compositions and methods for the prevention of oxidative degradation of proteins
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
SG171764A1
(en)
|
2008-12-16 |
2011-07-28 |
Millipore Corp |
Purification of proteins
|
|
CN105037535A
(zh)
|
2008-12-16 |
2015-11-11 |
Emd密理博公司 |
搅拌槽反应器及方法
|
|
SG173812A1
(en)
|
2009-02-27 |
2011-09-29 |
Genentech Inc |
Methods and compositions for protein labelling
|
|
AU2013205341B2
(en)
*
|
2009-03-20 |
2016-05-05 |
Amgen Inc. |
Alpha-4-beta-7 heterodimer specific antagonist antibody
|
|
WO2010107752A2
(en)
*
|
2009-03-20 |
2010-09-23 |
Amgen Inc. |
Alpha-4-beta-7 heterodimer specific antagonist antibody
|
|
AU2016208453B2
(en)
*
|
2009-03-20 |
2018-02-22 |
Amgen Inc. |
Alpha-4-beta-7 heterodimer specific antagonist antibody
|
|
NZ621170A
(en)
|
2009-05-13 |
2015-08-28 |
Genzyme Corp |
Anti-human cd52 immunoglobulins
|
|
HRP20200768T4
(hr)
|
2009-08-11 |
2025-03-28 |
F. Hoffmann - La Roche Ag |
Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
|
|
CN102686738A
(zh)
|
2009-09-01 |
2012-09-19 |
弗·哈夫曼-拉罗切有限公司 |
通过改进的a蛋白洗脱增强的蛋白质纯化
|
|
DK2493922T3
(en)
|
2009-10-26 |
2017-04-24 |
Hoffmann La Roche |
Process for preparing a glycosylated immunoglobulin
|
|
CA2792125C
(en)
|
2010-03-22 |
2019-02-12 |
Genentech, Inc. |
Compositions and methods useful for stabilizing protein-containing formulations
|
|
WO2011139718A1
(en)
|
2010-05-03 |
2011-11-10 |
Genentech, Inc. |
Compositions and methods useful for reducing the viscosity of protein-containing formulations
|
|
KR101551295B1
(ko)
|
2010-05-17 |
2015-09-08 |
이엠디 밀리포어 코포레이션 |
생체분자 정제용 자극 반응성 중합체
|
|
KR20190067277A
(ko)
|
2010-05-28 |
2019-06-14 |
제넨테크, 인크. |
락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
|
|
MY184736A
(en)
|
2010-06-24 |
2021-04-20 |
Genentech Inc |
Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
|
|
RU2013110844A
(ru)
|
2010-08-13 |
2014-09-20 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
|
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
|
LT2704742T
(lt)
|
2011-05-02 |
2017-10-25 |
Millennium Pharmaceuticals, Inc. |
Anti-alfa4beta7 antikūno kompozicija
|
|
US9938353B2
(en)
|
2011-06-24 |
2018-04-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
|
|
US10745468B2
(en)
|
2011-12-22 |
2020-08-18 |
Kota Biotherapeutics, Llc |
Compositions and methods for modified B cells expressing reassigned biological agents
|
|
HRP20181846T1
(hr)
|
2011-12-22 |
2018-12-28 |
Genentech, Inc. |
Kromatografija membranom za ionsku izmjenu
|
|
KR20140137347A
(ko)
*
|
2012-01-10 |
2014-12-02 |
더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 |
알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
|
|
EA201992881A3
(ru)
*
|
2012-01-12 |
2020-12-30 |
Милленниум Фармасьютикалз, Инк. |
Композиция анти-47 антитела
|
|
KR102096678B1
(ko)
|
2012-03-27 |
2020-04-02 |
제넨테크, 인크. |
재조합 단백질을 위한 개선된 수확 작업
|
|
CN103374073A
(zh)
*
|
2012-04-26 |
2013-10-30 |
中国科学院上海生命科学研究院 |
识别活化形式整合素α4β7的人源化单克隆抗体
|
|
SG11201407512VA
(en)
|
2012-05-18 |
2014-12-30 |
Genentech Inc |
High-concentration monoclonal antibody formulations
|
|
CN104994885B
(zh)
|
2012-12-19 |
2017-09-29 |
基因泰克公司 |
用于放射性卤素蛋白质标记的方法和组合物
|
|
AR095199A1
(es)
|
2013-03-15 |
2015-09-30 |
Genzyme Corp |
Anticuerpos anti-cd52
|
|
CN106686977B
(zh)
|
2014-07-09 |
2022-03-25 |
豪夫迈·罗氏有限公司 |
Ph调整以改善细胞库的解冻复苏
|
|
MA40592A
(fr)
|
2014-10-06 |
2016-04-14 |
Chemocentryx Inc |
Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7
|
|
WO2016086147A1
(en)
|
2014-11-26 |
2016-06-02 |
Millennium Pharmaceuticals, Inc. |
Vedolizumab for the treatment of fistulizing crohn's disease
|
|
US20170360926A1
(en)
|
2014-12-24 |
2017-12-21 |
Millennium Pharmaceuticals, Inc. |
PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY
|
|
MA41636A
(fr)
|
2015-03-06 |
2018-01-09 |
Millennium Pharm Inc |
Méthode de traitement de la cholangite sclérosante primitive
|
|
MX2018001668A
(es)
|
2015-08-11 |
2018-05-07 |
Univ Osaka |
Anticuerpo.
|
|
CA2996716A1
(en)
|
2015-09-04 |
2017-03-09 |
The California Institute For Biomedical Research |
Insulin immunoglobulin fusion proteins
|
|
WO2017117558A1
(en)
|
2015-12-31 |
2017-07-06 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications
|
|
KR102710759B1
(ko)
*
|
2016-03-14 |
2024-09-25 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
이식편대숙주 질환을 예방하는 방법
|
|
CA3017758A1
(en)
*
|
2016-03-14 |
2017-09-21 |
Millennium Pharmaceuticals, Inc. |
Methods of treating or preventing graft versus host disease
|
|
WO2017165742A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
|
|
WO2017165778A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
|
|
SG11201808562SA
(en)
|
2016-03-29 |
2018-10-30 |
Geltor Inc |
Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
|
|
MA44864A
(fr)
|
2016-05-04 |
2019-03-13 |
Icahn School Med Mount Sinai |
Trithérapie pour le traitement d'une maladie intestinale inflammatoire
|
|
WO2017214376A1
(en)
*
|
2016-06-10 |
2017-12-14 |
Elwha Llc |
Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function
|
|
WO2017218434A1
(en)
|
2016-06-12 |
2017-12-21 |
Millennium Pharmaceuticals, Inc. |
Method of treating inflammatory bowel disease
|
|
WO2018104893A1
(en)
|
2016-12-06 |
2018-06-14 |
Glaxosmithkline Intellectual Property Development Limited |
Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
|
|
MX2019007433A
(es)
|
2016-12-22 |
2019-08-16 |
Genentech Inc |
Metodos y formulaciones para reducir el tiempo de reconstitucion de los polipeptidos liofilizados.
|
|
WO2018200818A2
(en)
|
2017-04-28 |
2018-11-01 |
Millennium Pharmaceuticals, Inc. |
Method of treating pediatric disorders
|
|
CR20200076A
(es)
|
2017-07-14 |
2020-06-10 |
Pfizer |
ANTICUERPOS CONTRA MAdCAM
|
|
US11180541B2
(en)
|
2017-09-28 |
2021-11-23 |
Geltor, Inc. |
Recombinant collagen and elastin molecules and uses thereof
|
|
BR112020025623A2
(pt)
|
2018-07-03 |
2021-03-23 |
Bristol-Myers Squibb Company |
métodos de produção de proteínas recombinantes
|
|
MA53859A
(fr)
|
2018-10-10 |
2022-01-19 |
Boehringer Ingelheim Int |
Procédé de transfert de gaz de membrane dans une culture de bioréacteur à haute densité
|
|
AU2019387482A1
(en)
*
|
2018-11-30 |
2021-06-17 |
Memorial Sloan Kettering Cancer Center |
Heterodimeric tetravalency and specificity antibody compositions and uses thereof
|
|
WO2020205716A1
(en)
|
2019-04-01 |
2020-10-08 |
Genentech, Inc. |
Compositions and methods for stabilizing protein-containing formulations
|
|
SG11202111349QA
(en)
|
2019-04-12 |
2021-11-29 |
Geltor Inc |
Recombinant elastin and production thereof
|
|
MA55735A
(fr)
*
|
2019-04-17 |
2022-02-23 |
Millennium Pharm Inc |
Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23
|
|
AU2020290999A1
(en)
*
|
2019-06-10 |
2022-02-03 |
Takeda Pharmaceutical Company Limited |
Antibody purification methods and compositions thereof
|
|
TW202112819A
(zh)
*
|
2019-06-10 |
2021-04-01 |
美商千禧製藥公司 |
用於抗體製備之細胞培養方法及組合物
|
|
CN114514311A
(zh)
|
2019-08-01 |
2022-05-17 |
百时美施贵宝公司 |
改进补料分批细胞培养物中蛋白质产量的方法
|
|
EP4217383A1
(en)
|
2020-09-22 |
2023-08-02 |
Bristol-Myers Squibb Company |
Methods for producing therapeutic proteins
|
|
WO2023015234A1
(en)
|
2021-08-05 |
2023-02-09 |
Bristol-Myers Squibb Company |
Cell culture methods for producing therapeutic proteins
|
|
WO2023049687A1
(en)
|
2021-09-21 |
2023-03-30 |
Bristol-Myers Squibb Company |
Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
|
|
AU2023295521A1
(en)
|
2022-06-16 |
2025-01-02 |
Cephalon Llc |
Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
|
|
AU2024282654A1
(en)
|
2023-05-30 |
2025-12-04 |
Paragon Therapeutics, Inc. |
Alpha4beta7 integrin antibody compositions and methods of use
|
|
WO2024252368A2
(en)
|
2023-06-09 |
2024-12-12 |
Takeda Pharmaceutical Company Limited |
Methods and compositions for treating ulcerative colitis
|
|
WO2025137093A1
(en)
|
2023-12-19 |
2025-06-26 |
Cephalon Llc |
Uses for attenuated il-2 immunoconjugates
|
|
CN117777292B
(zh)
*
|
2023-12-28 |
2024-10-18 |
天津大学 |
抗整合素α4β7纳米抗体及其用途
|
|
WO2025149974A1
(en)
|
2024-01-11 |
2025-07-17 |
Takeda Pharmaceutical Company Limited |
Combination therapy with an anti-alpha4beta7 antibody
|
|
WO2025177214A1
(en)
|
2024-02-20 |
2025-08-28 |
Takeda Pharmaceutical Company Limited |
Therapeutic methods
|